unlikely to survive after 48 hours from screening or unlikely to remain at the investigational site beyond 48 hours. participants with multi organ dysfunction or requiring extracorporeal life support or renal replacement therapy were excluded. presence of neutropenia less than 2000/cubic millimeter (mmˆ3), aspartate transaminase or alt greater than 5x uln, platelets less than 50,000/mmˆ3. prior immunosuppressive therapies. use of systemic chronic corticosteroids for non-covid-19 related condition. known or suspected history of tuberculosis. suspected or known active systemic bacterial or fungal infections. the above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

unlikely to survive after 48 hours from screening or unlikely to remain at the investigational site beyond 48 hours. participants with multi organ dysfunction or requiring extracorporeal life support or renal replacement therapy were excluded. presence of neutropenia less than 2000/cubic millimeter (mmˆ3), aspartate transaminase or alt greater than 5x uln, platelets less than 50,000/mmˆ3. prior immunosuppressive therapies. use of systemic chronic corticosteroids for non-covid-19 related condition. known or suspected history of tuberculosis. suspected or known active systemic bacterial or fungal infections. the above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

unlikely to survive after 48 hours from screening or unlikely to remain at the investigational site beyond 48 hours. patients with multi organ dysfunction or requiring extracorporeal life support or renal replacement therapy are excluded. presence of neutropenia less than 2000/mmˆ3, ast or alt greater than 5 x uln, platelets less than 50,000/mmˆ3 prior immunosuppressive therapies use of systemic chronic corticosteroids for non-covid-19 related condition known or suspected history of tuberculosis suspected or known active systemic bacterial or fungal infections the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

unlikely to survive after 48 hours from screening or unlikely to remain at the investigational site beyond 48 hours. patients with multi organ dysfunction or requiring extracorporeal life support or renal replacement therapy are excluded. presence of neutropenia less than 2000/mmˆ3, ast or alt greater than 5 x uln, platelets less than 50,000/mmˆ3 prior immunosuppressive therapies use of systemic chronic corticosteroids for non-covid-19 related condition known or suspected history of tuberculosis suspected or known active systemic bacterial or fungal infections the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.